MarginsXMarginsX
Home › Markets › Health Care › ONCO

Onconetix Inc. (ONCO)

ONCO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.91
-9.35% on the day
Market cap
$1.9M
Nano cap
Revenue · 2025
$815K
-67.7% on 2024
Net income · 2025
-$14.0M
-1721.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/0001213900-26-027725-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerONCO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001782107
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$815K
Net income-$14.0M
Operating income-$17.9M
Net margin-1721.0%
Operating margin-2190.0%
Revenue growth-67.7%
Cash$5.2M
Total assets$24.9M
P/E (computed)Net income was not positive
P/S (computed)2.4×

Warning signs

Cash runway
6.9 months
$5.9M cash at June 30, 2026
Share count, 1 year
+12674.5%
2025-08-13 to 2026-08-13 · +3732088.3% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$8K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the date of the issuance of these consolidated financial statements."
10-Q 2026-08-13
Cash and burn$5.9M cash; operating cash flow -$2.6M a quarter.Report 2026-06-30
Shares outstanding394,911 (2026-08-13); 1,545,704 a year earlier; 17,988,058 three years earlier. 1y figure adjusted for splits (1-for-50 overall); 3y figure adjusted for splits (1-for-170000 overall).Cover page 2026-08-13
Reverse splits, 3 years5; latest 1-for-10 on 2026-11-06Source 2026-11-06
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMaloneBailey, LLP, Houston, Texas, United States; changed auditors 1 time in 24 months8-K 4.01 2025-02-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $153K, sold $144K on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 670,000 shares at the 2026-11-13 price; the latest SEC cover count is 394,911 as of 2026-08-13, 394,911 after the 1-for-10 split since. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$17K-$2.9M-$1.9M$5.9M$150K$646K10-Q 2026-08-13
Q1 2026
2026-03-31
$21K-$4.2M-$2.1M$3.7M$247K$735K10-Q 2026-05-13
Q4 2025
2025-12-31
$304K$5.7M-$3.1M$5.2MNo debt tags$815K10-K 2026-03-13
Q3 2025
2025-09-30
$304K-$8.8M-$3.2M$837K$160K$1.2M10-Q 2025-11-13
Q2 2025
2025-06-30
$106K-$2.4M-$1.4M$284K$8.7M$1.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$102K-$8.5M-$2.0M$1.6M$9.0M$1.9M10-Q 2026-05-13
Q4 2024
2024-12-31
$712K-$29.4M-$918K$647K$18.7M$2.5M10-K 2026-03-13
Q3 2024
2024-09-30
$407K-$3.8M-$1.1M$341K$9.8MNeeds four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-09-08
Latest annual report
ANNUAL REPORT
10-K2026-03-13
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-11-12
Latest proxy
CURRENT REPORT
DEFA14A2026-10-23

Source: SEC EDGAR submissions feed, 401 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-53.8%
1 month-42.2%
3 months-63.6%
Year to date-99.6%
1 year-99.7%
From 52-week high-99.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PPCBPropanc Biopharma Inc.$1.89-2.62%$2.0M
XRTXXORTX Therapeutics Inc. Common Shares$1.04-5.45%$1.9M
CMNDClearmind Medicine Inc. Common Shares$4.18-7.67%$2.1M
HCWBHCW Biologics Inc.$0.8000+3.48%$1.8M
SBFMSunshine Biopharma Inc.$2.60-3.70%$2.1M
DCOYDecoy Therapeutics Inc.$0.9010-7.61%$2.1M
SXTP60 Degrees Pharmaceuticals Inc.$0.4938-4.65%$1.7M
ENLVEnlivex Ltd.$1.12-5.88%$1.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier